Polyubiquitin chain topology is thought to direct modified substrates to specific fates, but this function-topology relationship is poorly understood, as are the dynamics and subcellular locations of specific polyubiquitin signals. experimental access to these questions has been limited because linkage-specific inhibitors and in vivo sensors have been unavailable. here we present a general strategy to track linkagespecific polyubiquitin signals in yeast and mammalian cells, and to probe their functions. We designed several high-affinity lys63 polyubiquitin-binding proteins and demonstrate their specificity in vitro and in cells. We apply these tools as competitive inhibitors to dissect the polyubiquitin-linkage dependence of nF-kB activation in several cell types, inferring the essential role of lys63 polyubiquitin for signaling via the il-1b and tnF-related weak inducer of apoptosis (tWeAK) but not tnF-a receptors. We anticipate live-cell imaging, proteomic and biochemical applications for these tools and extension of the design strategy to other polymeric ubiquitin-like protein modifications.
Polyubiquitin chain topology is thought to direct modified substrates to specific fates, but this function-topology relationship is poorly understood, as are the dynamics and subcellular locations of specific polyubiquitin signals. experimental access to these questions has been limited because linkage-specific inhibitors and in vivo sensors have been unavailable. here we present a general strategy to track linkagespecific polyubiquitin signals in yeast and mammalian cells, and to probe their functions. We designed several high-affinity lys63 polyubiquitin-binding proteins and demonstrate their specificity in vitro and in cells. We apply these tools as competitive inhibitors to dissect the polyubiquitin-linkage dependence of nF-kB activation in several cell types, inferring the essential role of lys63 polyubiquitin for signaling via the il-1b and tnF-related weak inducer of apoptosis (tWeAK) but not tnF-a receptors. We anticipate live-cell imaging, proteomic and biochemical applications for these tools and extension of the design strategy to other polymeric ubiquitin-like protein modifications.
The small protein-modifier ubiquitin is an essential signaling element in degradative and nondegradative processes that span nearly all of eukaryotic cell biology 1 . This functional diversity is explained in part by the structural diversity of ubiquitin modifications. Many forms of polyubiquitin are present in cells, each distinguished by the ubiquitin-ubiquitin linkages along the chain 1 . Ubiquitin has seven lysines and an α-amine that can each accept a ubiquitin C terminus in an (iso)peptide bond for chain formation 2 . The prevailing model holds that each structurally unique linkage type can recruit a distinct set of effectors that influence the fate of the modified protein 1, 3, 4 .
Mapping polyubiquitin topologies to functions inside cells is critical to validate this model and fully understand ubiquitin-dependent regulation. However, assessing this relationship has been particularly difficult. High endogenous expression and a multilocus gene structure make manipulation of ubiquitin pools in vivo cumbersome or impossible outside of a few model systems such as yeast 5, 6 or specially constructed cell lines 7 . Linkage-specific probes for live cells have not been available. In vitro, different polyubiquitin linkages can be identified by mass spectrometric methods 2 , but similarly to many post-translational modifications, polyubiquitination is highly dynamic, and low abundance of polyubiquitin conjugates has limited application of these approaches. Thus, though much of the proteome is subject to polyubiquitination, little is known about how linkage type relates to the functions and fates of those modified proteins 1, 4 . Evidence supports that polyubiquitin assembled through Lys48 (Lys48-polyUb) is a dedicated signal for proteasome recruitment and substrate degradation throughout the cell 8 , whereas Lys63-polyUb serves nonproteasomal roles in DNA repair 9, 10 , autophagy and organelle clearance 11 , endocytosis 12 and inflammation signaling 13 . Even for these examples, the extent to which other polyubiquitin topologies may also serve these functions, the dynamics of these signals in cells and the relationship between subcellular localization and signaling fidelity are essentially unknown and difficult to examine with current methods.
To address this deficit, we developed sensors that could be expressed in cells to localize or inhibit specific polyubiquitin signals. Building on structural analyses and principles of linkage-specific avidity 14, 15 , we created high-affinity polyubiquitinbinding proteins from multiple tandem ubiquitin-interacting motifs (tUIMs) with structured linker regions that direct binding to Lys63-polyUb. These proteins localized to Lys63-specific structures when expressed in cells, and can be applied as inhibitors to diagnose the linkage-type dependence of polyubiquitin signaling in virtually any cell type.
results

Avidity design for linkage-specific polyubiquitin binding
We have previously described how the short linkers between domains in naturally occurring tUIM proteins can determine polyubiquitin linkage specificity by promoting avid interactions with multiple ubiquitin units in a particular configuration 14 .
Helical 7-amino-acid linkers position two-UIM peptides for optimum avid binding across a single Lys63 linkage but not to other linkage types or monoubiquitin. Whereas 8-amino-acid linkers are near-optimum for Lys63 binding, 6-amino-acid helical linkers confer low affinities for Lys63-polyUb because they position the ubiquitin-binding sites out of helical phase with each other (Fig. 1a,b) . We extended this natural strategy to create Vx3, a three-UIM peptide with the relatively tight-binding Vps27 UIM domains (dissociation constant (K d ) monoubiquitin = 100-200 µM; ref. 16 ) and weakly helical 7-amino-acid linkers. Vx3 bound Lys63-polyUb with K d of 4.4 nM, a 70-fold preference over Lys48-polyUb, and a 2,700-fold preference over linear (α-amine-linked) polyubiquitin.
Consistent with the principle that more-structured linkers provide higher affinity and specificity, strongly α-helical heptaalanine linkers (Supplementary Fig. 1 ) improved the affinity and specificity of Vx3 ( Table 1) ; we named this peptide Vx3(A7). This peptide bound to Lys63-linked tetraubiquitin (Lys63-Ub4) more tightly than we could accurately measure, with K d ≤ 200 pM (Supplementary Fig. 1 ). In spite of the improved Lys63-linkage specificity, we reasoned that the range of concentrations over which Vx3(A7) was highly linkage-specific (0.01-1 nM) was too low to be useful in cells because physiological concentrations of non-Lys63-linked species probably exceed 1 nM in some cases; total cellular ubiquitin may vary several fold, up to 85 µM, with ~10% distributed among mostly Lys48-, Lys63-and Lys11-linked polyubiquitin conjugates 2, 17 .
To shift the high-specificity regime to high-nanomolar concentrations, we paired the weaker UIMs from human Rap80 (K d monoubiquitin = 500-1,000 µM (ref. 14)) with all-alanine linkers to create Rx3(A7) (Fig. 1c) . Rx3(A7) bound Lys63-polyUb as tightly as Vx3 did (K d for triubiquitin (K d Ub3 ) = 5 nM) but with additional specificity conferred by the highly structured linkers. We measured a 1,100-fold preference for Lys63-polyUb over Lys48-polyUb, and a 23,000-fold preference over linear polyubiquitin. Binding to Lys11-polyUb was too weak for us to saturate, but the preference for Lys63-polyUb over Lys11-polyUb probably exceeds 3,300-fold (Table 1 and Fig. 1d ). Rx3(A7) therefore displays high linkage specificity for Lys63-polyUb over a broad concentration range that likely encompasses typical cellular polyubiquitin levels (Fig. 1d) . Although this range is narrower for Vx3 (Table 1) , as described below, in many applications Rx3 and Vx3 can be used with qualitatively similar effects. As expected from structural modeling (Fig. 1b) , an 8-alanine linker conferred weak Lys63-polyUb binding in the three-UIM context (Rx3(A8)), and Rx3(A6) had even lower affinity (K d = 160 nM and 2,900 nM, respectively; Supplementary Fig. 1 ).
These results indicated that linkage-specific avidity may be applied to produce polyubiquitin-binding reagents of arbitrarily high affinity and with linkage specificities that rival or exceed those of linkage-specific polyubiquitin antibodies 18, 19 . Indeed, biotin-labeled Vx3 bound specifically to Lys63-polyUb chains immobilized on a membrane and thus may be used to identify polyubiquitin types much like an antibody in immunoblot and other biochemical applications (Fig. 1e) . Unlike antibodies, however, these reagents may be easily expressed inside living cells; here we focus on these applications.
intracellular lys63-polyub structures and dynamics
We transiently expressed tUIM fusions to monomeric enhanced GFP (mEGFP) in cultured human cells. Both Vx3-mEGFP and Rx3(A7)-mEGFP were somewhat excluded from the nucleus and localized to large perinuclear foci that vary widely in appearance from cell to cell ( Fig. 2a and Supplementary Fig. 2 ). Similar structures have been observed in cells examined by immunofluorescence with antibodies to Lys63-polyUb 19 . A subset of these foci localized with markers of autophagic vesicles (Fig. 2c) , a subset of which localized with the DNA double-strand break (DSB) marker γH2AX (see below). We found that some Vx3 fused to mEGFP or EGFP (Vx3-EGFP) was apparently ubiquitinated in human cells (≤10%; data not shown), an unwanted modification that could be eliminated by lysine-to-arginine substitutions in the tUIM sequence. The thus altered peptide, Vx3K0, was virtually indistinguishable from Vx3 with respect to in vitro polyubiquitin affinity ( Table 1) , subcellular localization and inhibitory activity (see below). Taken together, these results indicate that the cellular structures revealed by the Vx3 and Rx3(A7) proteins were ubiquitin-specific, but were not the result of a generic ubiquitin-binding capacity. Instead, these peptides appeared to localize to cellular structures through interactions with specific polyubiquitin topologies. To determine the linkage-type dependence of the cytosolic aggregates that Vx3K0-mEGFP and Rx3(A7)-mEGFP bind in vivo, we used yeast strains previously engineered to express ubiquitin from a single transgene (single-ubiquitin yeast) 5 . We compared Vx3K0-EGFP localization in yeast strains expressing wild-type ubiquitin (single-ubiquitin-wild-type strain) or a K63R mutant ubiquitin that can produce all polyubiquitin topologies except Lys63-linked (single-ubiquitin-K63R strain) 6 . Similar to its pattern in human cells, Vx3K0-EGFP localized to large, mostly perivacuolar structures in single-ubiquitinwild-type yeast but not in single-ubiquitin-K63R yeast ( Fig. 2g-i) . The pattern of binding-deficient Vx3NB-EGFP was diffuse in both strains, as expected ( Supplementary Fig. 2 ). Vx3K0-EGFP expressed in wild-type yeast (not single-ubiquitin yeast) was localized as it did in the single-ubiquitin wild-type strain, indicating that this pattern was not an artifact of the strain manipulation used to replace ubiquitin.
Next we used Vx3-EGFP to track Lys63-polyUb signals in live cells. The E3 ubiquitin ligase Parkin translocates to damaged mitochondria where it promotes Lys63 polyubiquitination of multiple substrates 20, 21 . The damaged organelles are ultimately condensed into perinuclear aggregates for processing by autophagic degradation 22 . We transfected plasmids encoding YFP-Parkin alone or Vx3K0-EGFP with unlabeled Parkin into HeLa cells stably expressing the mitochondrial marker mito-dsRed and treated the cells to depolarize the mitochondria. Consistent with previous reports, YFP-Parkin rapidly localized to damaged mitochondria (Fig. 3a) ; this was followed by recruitment of Vx3K0-EGFP, presumably by Lys63-polyUb-conjugated mitochondrial proteins (Fig. 3b,c) . This activity required the ubiquitin-binding residues of Vx3 and, as HeLa cells do not express the ligase, an active, exogenous Parkin ( Supplementary Fig. 3 ). These results indicate that our designed proteins can localize Lys63-polyUb-modified conjugates dynamically inside cells. Note that clustering of damaged mitochondria was somewhat reduced in cells also expressing Vx3K0-EGFP (Fig. 3a,b) . As clustering is thought to be promoted by binding of p62 to Lys63-polyUb at the mitochondrion 21 , this suggests that the Lys63-polyUb was masked by bound Vx3. However, because the extent of clustering can vary with the expression levels of Vx3K0-EGFP or Parkin, this mechanism, though likely, is speculative. npg
Polyubiquitin sensor proteins as inhibitors of cellular signaling
Ubiquitin recognition by natural receptors usually is limited to a small set of residues 3 and thus typically excludes simultaneous binding by other receptors or deubiquitinating enzymes. For this reason, we expected that expression of Lys63-specific polyubiquitin sensors may inhibit Lys63-dependent signaling and specifically prevent deubiquitination of these conjugates ( Supplementary Fig. 4 ). Indeed, expression of Rx3(A7)-mEGFP in HeLa cells for 20 h doubled Lys63-conjugates as measured by quantitative immunoblot (Fig. 4a,b) . Total polyubiquitin, Lys48-polyUb and unconjugated ubiquitin in these cells were largely unchanged compared to control (encoding Vx3NB-mEGFP) transfected cells, though the polyubiquitin species appeared partially shifted to higher-molecular-weight forms. These results are consistent with the in vitro linkage specificities of the polyubiquitin sensor proteins and indicate that these constructs may specifically inhibit the action of endogenous Lys63-polyUb effectors in cells.
To test this, we expressed Vx3 fused to maltose binding protein (MBP-Vx3) in wild-type yeast from high-or low-copy plasmids (Fig. 4c) . We compared these strains for their resistance to the arginine analog canavanine or the genotoxic alkylating agent methyl methanesulfonate (MMS), which are previously described phenotypes attributed to the capacity to make Lys63-polyUb 6, 23 . Yeast expressing MBP-Vx3 variants from highcopy plasmids were nearly as sensitive to canavanine as the single-ubiquitin-K63R strain (Fig. 4c) . We did not identify the impaired function that results in canavanine sensitivity in Vx3-expressing cells, although prominent possibilities include defective arginine permease downregulation and impaired turnover of misfolded canavanine-containing proteins. Next we examined yeast growth in the presence of MMS, in which Lys63-polyUb-modified proliferating cell nuclear antigen (PCNA) at sites of MMS-caused DNA damage is required to recruit specialized damage-tolerance machinery 9 . MBP-Vx3 expression restricted growth on MMS-containing plates in a dose-and compartment-specific manner. Yeast expressing NLS-MBP-Vx3 from a low-copy CEN plasmid showed inhibited growth in the npg presence of MMS, and yeast expressing NLS-MBP-Vx3 from the high-copy 2µ plasmid were as sensitive to MMS as the singleubiquitin-K63R yeast (Fig. 4c) . Constructs lacking the NLS did not accumulate in the nucleus (as assessed using an EGFP fusion) and had no effect. We also examined the effect of NLS-Vx3-EGFP expression on DNA DSB repair in mammalian cells, where Lys63-polyUb similarly recruits repair factors to damage sites. Expression of NLS-Vx3-EGFP in ionizing radiation-treated cells did not affect formation of γH2AX-containing foci but severely delayed the disappearance of these foci (Fig. 4d,e) . This is consistent with the proposed role for Lys63-polyUb downstream of the γH2AX modification at DSBs but upstream of repair factors important for clearance such as Rap80 and BRCA1 (ref. 10) , and suggests that NLS-Vx3-EGFP inhibits DSB processing at these sites by blocking access of Rap80 and other repair factors to Lys63-modified substrates. In response to ionizing radiation, monomeric (m)Cherry-Rap80-containing foci were reduced in cells expressing NLS-Vx3-EGFP as compared to cells expressing the Vx3NB-EGFP negative control (median numbers of mCherry-Rap80 foci per cell were 5 and 19, respectively; P < 0.0001, n = 60) (Fig. 4f) . These results establish that our designed proteins can inhibit Lys63-polyUb signaling in cellulo and suggest that they act by displacing endogenous receptors of polyubiquitin signals.
linkage-specific polyubiquitin in nF-kB activation
To address linkage specificity and inhibitory activity in cells, we sought a functional assay in which inhibitor expression amounts could be linked to related outcomes with known Lys63-polyUb and non-Lys63-polyUb dependences. Ligand-mediated NF-κB activation is an ideal test case because recent reports have illuminated the divergent polyubiquitin landscape downstream of two important cell-surface receptors, interleukin-1 receptor (IL-1R) and tumor necrosis factor receptor (TNFR).
Both IL-1R and TNFR signaling follow the canonical NF-κB activation pathway (namely, ligand binding to a receptor, inhibitor of kappa B kinase (IKK) activation and nuclear translocation of the NF-κB transcription factor) 13, 24 . Nondegradative polyubiquitin chains formed on one or more substrates (for example, kinase receptor interacting protein-1, RIP-1) near the receptor serve as a signaling platform to recruit a polyubiquitin-binding subunit of IKK for activation. Originally, these chains were thought to be Lys63-linked for both TNFR and IL-1R signaling. However, a ubiquitin-replacement strategy 7 in the human U2OS osteosarcoma cell line showed that, when the sole source of ubiquitin was Ub(K63R), IL-1β-mediated IKK activation was completely abrogated, whereas activation in the TNF-α-stimulated pathway was unaltered. More recently, mass spectrometry and linkage-specific immunoblot analyses indicated that Lys63-and Lys11-linked chains are present at the TNFR in roughly equal proportions after treatment with TNF-α 25 . The apparent resolution of these two studies is that IL-1β signaling is strictly dependent on Lys63-polyUb, whereas signaling through the TNFR can function with Lys11-polyUb alone, although the typical polyubiquitin complement is a poorly defined mix of Lys11 and Lys63 linkages. Thus, a stringent test of our inhibitor proteins is the ability to discriminate these distinct polyubiquitin dependencies in otherwise highly similar pathways.
We examined IL-1β-and TNF-α-stimulated NF-κB activation in U2OS cells in the presence of retrovirally transduced Rx3(A7)-mEGFP or, as a negative-control, Vx3NB-mEGFP. We tracked activation status in single cells by immunofluorescence detection of the endogenous NF-κB subunit p65, which translocates from the cytosol to the nucleus upon activation by either ligand (Online Methods). As expected, p65 was cytosolic (translocation score 0) in unstimulated cells but nuclear (translocation score 1) in IL-1β− or TNF-α-treated cells after 30 min (Fig. 5a) . Rx3(A7)-mEGFP inhibited NF-κB activation in IL-1β-stimulated cells at all expression levels (Fig. 5a,b) . At the lowest measurable mEGFP concentrations inhibition was incomplete but rapidly reached saturation upon higher Rx3(A7)-mEGFP expression, consistent with high affinity of the Rx3(A7)·Lys63-polyUb interaction ( Table 1) . In contrast, activation in TNF-α-treated cells was unaffected by low doses of Rx3(A7)-mEGFP (Fig. 5a,b) and, compared with stimulation by IL-1β, required about tenfold more inhibitor (as measured by mEGFP intensity) to prevent p65 translocation. At low expression levels, where we expect the inhibitor proteins to be most specific, Rx3(A7)-mEGFP clearly distinguished the linkage-type dependences of these two ligandmediated NF-κB pathways and thus functioned as a linkagespecific inhibitor of cellular polyubiquitin signaling. We also found that inhibition by Vx3K0-mEGFP could distinguish IL-1β and TNF-α signaling in U2OS cells, though with a somewhat smaller window of inhibitor concentrations over which we observed linkage specificity (Supplementary Fig. 5) .
To explore the relationship between in vitro linkage specificities and inhibitor activity in cells, we evaluated the effects of each of our tUIM-mEGFP fusions on TNF-α signaling in HeLa cells. Consistent with its higher in vitro Lys63-linkage specificity, higher cellular concentrations of Rx3(A7) were required to inhibit activation as compared to Vx3K0-mEGFP (Fig. 5b,c) ; we suspect that, consistent with its lower linkage specificity in vitro, Vx3K0 is a slightly better binder for the non-Lys63-polyUb species involved in TNFR signaling. Rx3(A8)-mEGFP showed greatly reduced inhibitory activity, and Rx3(A6)-mEGFP was virtually indistinguishable from the Vx3NB nonbinding control (Fig. 5c) . These data suggest that the inhibition observed is due to binding to specific polyubiquitin topologies.
These inhibitor profiles highlight the requirement to account for polyubiquitin sensor expression to distinguish Lys63-dependent from non-Lys63-dependent signaling; with very high Rx3(A7)-mEGFP expression, both IL-1β and TNF-α signaling were completely inhibited, presumably because of weak 'off-target' interactions with non-Lys63-polyUb chains such as homogeneous Lys11-polyUb or perhaps a mixed Lys63 and Lys11-containing polyUb species. To establish an upper limit of cellular inhibitor expression for linkage-specific action, we determined the halfmaximal inhibitory concentration (IC50) of TNF-α inhibition by Rx3(A7)-mEGFP in HeLa cells by calibrating image data to quantitative immunoblots. With TNF-α signaling inhibition as a marker for non-Lys63 binding, we determined that Rx3(A7)-mEGFP above 16 µM no longer showed strong Lys63-linkage preference (Supplementary Fig. 6 ). This concentration agreed closely with our in vitro polyubiquitin binding constants for nonLys63-linked chains (Table 1) , particularly when considering that effective intracellular inhibitor concentrations must be slightly lower than this because some Rx3(A7)-mEGFP typically is in perinuclear aggregates. By our estimate, the expression required for linkage-specific inhibition is well below that achievable from npg typical transient transfection of cultured cells (Fig. 5d) ; therefore, care must be taken when applying these reagents to either account for cellular inhibitor levels explicitly in single cells or, by adjusting average inhibitor expression levels (for example, through optimized transfection or a tunable induction strategy), to be within the linkage-specific concentration regime of the inhibitor.
Next, we examined signaling through the TWEAK receptor FN14. TWEAK ligand is a physiological activator of NF-κB that acts through signaling mechanisms that are largely unknown with respect to polyubiquitin 26 . The ubiquitination enzymes UbcH5 and c-IAP1 are important downstream components of both TWEAK-and TNF-α-mediated NF-κB activation 25, 27 . To determine whether these pathways have a common polyubiquitinlinkage dependence, we retrovirally transduced inhibitor and control constructs into mouse embryo fibroblasts (MEFs), a cell type that gives robust and reproducible activation of NF-κB by TWEAK. TWEAK-receptor signaling was inhibited at very low Vx3K0-mEGFP concentrations, identical to the inhibition of the strictly Lys63-dependent IL-1β signaling in both MEFs and U2OS cells (Fig. 5b,e) . We infer from this assay that TWEAK-mediated NF-κB activation showed the same strict requirement for Lys63-polyUb as the IL-1β pathway. These results showed that our linkagespecific proteins may be applied across cell types to diagnose polyubiquitin linkage-type dependences of cellular processes.
discussion
Relative to a single ubiquitin-binding domain (UBD), arrays of UBDs can exhibit enhanced affinities for polyubiquitin; however, such high-affinity polyubiquitin-binding proteins are not necessarily linkage-specific 28 . Here we described highly linkagespecific polyubiquitin-sensor proteins from tUIMs with helical 7-amino-acid linkers. tUIM linkers of lengths other than those used here and other intrinsic structures may direct binding to yet other polyubiquitin topologies; the natural complement of human tUIM linkers includes a wide variety of lengths and apparent structures, including 2-amino-acid linkers that confer Lys48-polyUb selectivity 14 . Moreover, although the tUIM format is the most straightforward for creating avidity-based polyubiquitin sensors, inserting UBDs into globular proteins or oligomeric protein scaffolds may provide a wider range of conformations from which to select affinity reagents for other polyubiquitin structures 15 . We demonstrated here that multiUBD constructs may be manipulated at two levels to create linkage-specific polyubiquitin affinity reagents: individual UBD-ubiquitin binding primarily influenced overall affinity, whereas the orientation and rigidity of multiUBD arrangements influenced linkage specificity. As topological complexity is increasingly revealed for other polymeric ubiquitin-like proteins such as polySUMO 4 , this aviditybased design strategy similarly may be applied to create a wide range of polyubiquitin and poly(ubiquitin-like) affinity reagents. Antibodies are limited to the recognition of small epitopes, so it is difficult to envision a single antibody reagent targeted to a mixed polymer such as ubiquitin-Lys63-ubiquitin-Lys11-ubiquitin or ubiquitin-SUMO-ubiquitin. In contrast, our avidity-based design strategy theoretically can produce affinity reagents to complex polymer species by directing simultaneous interactions across multiple ubiquitin or ubiquitin-like linkages. We note also the potential for these reagents (and the avidity-based design strategy) to inform the search for and application of small-molecule inhibitors of specific polyubiquitin topologies 29 .
Linkage-specific polyubiquitin antibodies are increasingly available and have proven to be quite useful 18, 19, 30 . However, the requirement for disulfide-bond formation for proper folding and function of typical immunoglobulins limits those tools to mostly in vitro applications. We anticipate optimization of our probes for live-cell applications, including the possibility of fluorescence resonance energy transfer-based sensors that exploit conformational shifts expected for some tUIM peptides upon polyubiquitin binding 14 . As intracellular inhibitors, the contributions of subcellular localization to polyubiquitin signaling may be explored by appending targeting sequences to the protein fusions. Finally, because the sensor proteins inhibit deubiquitination (Fig. 4a,b) , their expression in cells may allow the accumulation of otherwise unstable polyubiquitin conjugates to amounts sufficient for isolation and identification. However, as our study showed, sensor-protein concentration must be carefully controlled to npg avoid off-target binding that is increasingly favored above the dissociation constant for Lys63-polyUb (Fig. 5d) . Unlike ubiquitin-replacement strategies in mammalian cells that require the coordinated inducible expression and knockdown of multiple ubiquitin genes 7 , our inhibitor strategy is easily applied to any cell line, tissue-type or organism that can be transfected or virally transduced. Moreover, this type of study should be extensible (for example, via microscopy or FACS) to any cellular function with a scorable single-cell phenotype. Recent studies of TNFR-mediated signaling underscore key differences in the available approaches to study linkage-specific polyubiquitin functions. Ubiquitin-replacement strategies restrict which linkages can be made and thus can reveal a specific ubiquitinubiquitin linkage requirement 2, 6 , but no effect will be observed if an alternative linkage-type can serve an equivalent signaling role. Conversely, mass spectrometry and linkage-specific immunoblot approaches reveal which linkages are present 25 but give no information about their relative importance for function. Our linkage-specific inhibitor strategy combines useful aspects of both approaches by linking competitive inhibition of naturally assembled polyubiquitin signals to a functional outcome. Lastly, unlike ubiquitin-replacement strategies used to manipulate ubiquitin pools in vivo, expression of polyubiquitin-sensor proteins caused dose-sensitive and thus (most likely) reversible Lys63-polyUb-associated phenotypes. This makes possible genetic screen approaches to identify function-specific Lys63-polyUb receptors, whose overexpression may restore function by moving receptors into concentration regimes where they can effectively compete with inhibitors for Lys63-polyUb binding. online methods Plasmids and proteins. We created designed tUIM genes by overlapping primer-extension PCR with 20-40-base oligonucleotides. Cloning and sequence details are summarized in Supplementary  Tables 1 and 2 . mEGFP used in fusion proteins has been described previously 31 . For binding assays, we bacterially expressed His 6 -tagged tUIMs and purified them using Ni-NTA agarose (Qiagen) according to the manufacturer's directions. We labeled recombinant tUIMs on a single cysteine residue with fluorescein maleimide or biotin maleimide (Pierce), and then purified them by gel-filtration or anion-exchange chromatography as needed. We produced polyubiquitin chains of defined length and linkage as previously described 32, 33 .
Polyubiquitin binding assays. We performed direct fluorescence anisotropy binding titrations as described previously 14 , with fluorescently labeled peptide present at 1 nM, 4 nM, 10 nM or 100 nM in the cuvette, depending on the anticipated affinity of the peptide being tested. We made binding measurements at 25 °C in fluorescence buffer (25 mM Na phosphate pH 7.4, 150 mM NaCl, 5 mM β-mercaptoethanol, 1 mM EDTA and 0.05% Brij35). To reduce the amount of polyubiquitin needed to determine K d values for weakly binding proteins, we performed some titrations in a competition assay format (Supplementary Fig. 1 ). Typically, we combined fluorescein-labeled binding peptide (for example, 4 nM fluorescein-Vx3) with polyubiquitin (for example, 50 nM Lys63-Ub3) to give ~80% saturation; we determined fluorescence anisotropy values with various amounts of unlabeled competitor protein and fit K d values with a model of competitive binding to a single site; we derived baseline anisotropy values from samples with no competitor protein and the plateau value from fluorescent binding protein without polyubiquitin ligand. Where relatively weak binding was measured, high protein concentrations (>10 µM) caused anisotropy values to increase slightly because of changes in the solution viscosity. In those cases, we determined corrections for the viscosity effects by titrations of fluorescent binding peptide with competitor protein in the absence of polyubiquitin. For the far-western dot blot, we spotted the indicated amounts of purified ubiquitin species in binding buffer plus 1 mg ml −1 BSA directly onto dry polyvinylidene fluoride (PVDF) membrane and allowed them to dry completely. We blocked the methanol-wetted membranes in 3% BSA, probed the membranes with 30 nM biotinylated His 6 -Vx3 peptide, washed them in pH 7.4 Tris-buffered saline with 0.05% Tween-20 (TST), probed them with streptavidin-horseradish peroxidase (HRP) (Pierce) and washed them again with TST; detection was by chemiluminesence. Antibodies with specificity to total polyubiquitin were from Millipore (clone FK2) and antibodies to unanchored ubiquitin were from Epitomics (ubiquitin C terminus antibody; clone RPS27A; 1:1,000 dilution).
Yeast and mammalian cell culture. We cloned MBP-Vx3 and NLS-MBP-Vx3 into pRS415-ADH (low-copy CEN plasmid) or pRS425-ADH (high-copy 2µ plasmid), each containing the constitutive alcohol dehydrogenase (ADH) promoter. We transformed these into wild-type yeast strain BY4741 (MATa leu2∆0 his3∆1 ura3∆0 met15∆0) and transformants were selected on synthetic complete medium without leucine (SC -Leu). In the original (SUB280-derived) single-ubiquitin yeast strains, LEU2 was used to replace UBI4. To recover the leu2 marker in these strains, we replaced via homologous recombination the LEU2 gene at the UBI4 locus with a cassette that conferred hygromycin resistance. We selected hygromycin-resistant leucine auxotrophs and confirmed the proper integration by PCR. For yeast growth assays, we grew two independent transformants from each transformation to mid-log phase in SC -Leu and spotted 0.25 OD 600 equivalents (~3 × 10 6 cells) in serial tenfold dilutions on the following plates: SC -Leu (control), SC -Leu containing 0.025% methyl methanesulfonate (MMS), or SC -Leu -Arg containing 0.0001% canavanine.
HeLa cells and MEF lines were maintained in Dulbecco's modified Eagle medium (DMEM), and U2OS cells were grown in McCoy's medium, both media were supplemented with 10% FBS, 100 international units (I.U.) penicillin and 100 µg ml −1 streptomycin. We introduced mCherry-Rap80 into Rap80 −/− MEFs (gift of J. Chen, University of Texas M.D. Anderson Cancer Center) by retroviral transduction, followed by IL-2Rα-mediated beadsorting to select a population of cells that stably express the construct. We introduced polyubiquitin sensor constructs by lipid transfection using Lipofectamine 2000 (Invitrogen) or Fugene6 (Roche), or by retroviral transduction using the RetroX packaging cell line (Clontech). Confluent HeLa cells in six-well dishes transfected with 1 µg of inhibitor or control plasmids were used for ubiquitin immunoblot analysis. We lysed cells on ice for 30 min in PBS with 1% Triton X-100, 20 mM NEM, 10 mM EDTA and mini-Complete protease inhibitor cocktail (Roche). Antibodies in experiments shown in Figure 4a were used according to the manufacturer's instructions, and immunoblots were quantified using IR800 secondary antibodies (LI-COR).
Microscopy. For imaging Vx3-EGFP in the single-ubiquitin yeast strains, we cloned Vx3K0-EGFP and NLS-Vx3K0-EGFP into pRS425-ADH, transformed them into yeast strains BY4741 or SUB280 (ref. 6) (expressing wild-type or Lys63Arg ubiquitin), and selected transformants on SC -Leu. We fixed mid-log phase cells for 1 h with 3.7% formaldehyde, washed them with PBS and then examined using a 100× objective. For HeLa and MEF imaging, we fixed cells 18 h after transfection with 2% paraformaldehyde for 10 min, mounted them using ProLong Gold antifade medium (Invitrogen) with DAPI, and imaged the cells with a 60× objective and deconvolution. We transiently transfected Rap80 −/− MEFs expressing mCherry-Rap80 with NLS-Vx3K0-EGFP or Vx3NB-EGFP by using Fugene6 reagent. After 24 h, we exposed cells to 3 Gy of γ-irradiation and allowed them to recover for 30 min at 37 °C before fixation with 2.5% paraformaldheyde. We mounted cells on slides using ProLong Gold medium and acquired fluorescence images with an Olympus IX81 spinning-disk confocal microscope (CSU22 head) using a 60×, NA 1.42 oil objective. For the γH2AX foci counts, we irradiated HeLa cells (1 Gy) 24 h after transient transfection. After the indicated recovery times, we fixed cells in 2.5% paraformaldehyde for 10 min, permeabilized them in 0.1% Triton X-100, stained them with anti-phospho-histone H2A.X (Ser139) (clone JBW301, Upstate) for 2 h at 1:100 dilution, incubated them with Alexa Fluor 594 antimouse IgG (Invitrogen; 1:300 dilution), counterstained nuclei with DAPI and mounted the coverslips on slides using ProLong Gold. For statistical analyses of foci counts we used the nonparametric Wilcoxon rank-sum test. For mitophagy experiments, we imaged live cells in CO 2 -independent media (Invitrogen) npg nAture methods using an UltraView LCI confocal microscope (PerkinElmer) at 37 °C with a 63×, numerical aperture (NA) 1.4 Apochrome objective. We used Volocity software (PerkinElmer) for analysis. We calculated the fluorescence intensity of the YFP or mEGFPtagged proteins in the area of the mitochondria, normalized this to the total cell YFP or mEGFP, and set the start value to one. For fixed-cell mitophagy controls (Supplementary Fig. 3) , we plated HeLa cells onto chambered cover glasses, where they were cultured overnight. We then transiently transfected the cells with Vx3K0-EGFP or Vx3NB-EGFP plasmids. The next day, we treated cells with 10 µM CCCP for 3 h, then fixed and stained them for the mitochondrial marker Tom20 (Tom20 polyclonal antibody; Santa Cruz, sc-11415). We collected fixed-cell images on a Zeiss LSM 510 confocal microscope using a 63×, NA 1.40 Apochrome objective. We adapted the staining protocol for LC3 (Supplementary Fig. 2 ) from a method provided by J. Gutierrez (Millennium-Takeda Pharmaceuticals). Twenty-four hours after transfection (with Lipofectamine 2000) we fixed cells with 2.5% paraformaldehyde for 10 min, permeabilized them with 100 µg ml −1 digitonin for 15 min, and blocked for 1 h with 0.5% blocking reagent (Roche) in 100 mM Tris pH 7.5 and150 mM NaCl. Then we incubated the cells with LC3 antibody (clone 4E12, MBL International; 1:300 dilution) overnight at 4 °C, stained the sample with Alexa Fluor 594 anti-mouse IgG, and mounted the coverslips on slides using ProLong Gold medium. We obtained fluorescence images with the Olympus IX81 spinning-disk confocal microscope using a 100×, NA 1.4 oil objective.
NF-κB activation experiments.
We measured NF-κB activation at the single-cell level by fluorescence microscopy 34 . We plated U2OS cells (5,000 cells), HeLa cells (9,000 cells) or MEFs (5,000 cells) in clear-bottom 96-well imaging plates. After overnight growth, we transfected or retrovirally transduced the cells as described above; we changed the medium 18-24 h after transfection or transduction and 1 h before the ligand stimulation. We added TNF-α (PeproTech) or IL-1β (Pierce) to the growth medium at 10 ng ml −1 , and TWEAK (PeproTech) at 100 ng ml −1 . All doses were the minimum that gave reproducible p65 translocation after 30 min. We chose the 30 min time point to avoid the potential complications of apoptosis and autocrine signaling from NF-κB transcriptional targets, both of which have been shown to occur at longer times 35, 36 . After stimulation, we fixed cells as above, permeabilized them in PBS with 0.2% Triton X-100 for 10 min, blocked with LI-COR Blocking Buffer, incubated with p65 monoclonal antibody (F-6, Santa Cruz) diluted 1:300 in blocking buffer, washed and stained the plates with Alexa Fluor 647-conjugated anti-mouse IgG (Invitrogen) diluted 1:2,000 in blocking buffer. We stained DNA and total protein with a combination of Hoechst 33342 (Invitrogen) and Whole Cell Stain Blue (Pierce). Images were collected at 10× magnification by automated microscopy (ArrayWorx, API).
We used the custom image analysis software Imagerail 34 to define cell and nuclear boundaries from empirical threshold values determined on the blue channel. After segmentation, we gated out untransfected cells from the analysis based on mEGFP intensity. We removed the small number of deformed, dead or incorrectly segmented cells from the analysis by gating on features of cell size, nuclear size and the ratio of nuclear-to-cytoplasmic intensities on the blue and green channels. Finally, we measured p65 translocation as the ratio of nuclear-to-cytoplasmic staining for each cell on the Cy5 (Alexa Fluor 647) channel. Measuring the disappearance of IκBα at earlier time points (15 min and 20 min) was less robust but gave very similar results with respect to TWEAK and IL-1β inhibition (data not shown). We assigned a p65 translocation score of 0 to the average nuclear/cytoplasmic p65 ratio for unstimulated control cells (Vx3NB-mEGFP) and 1 for the control cells treated with ligand. Untransfected and control-transfected cells gave very similar responses in terms of p65 translocation. We then scaled the nuclear/cytoplasmic ratio for cells transfected with inhibitor proteins between 0 and 1 based on the control-cell analysis.
Control experiments established the equivalence of Vx3NB-EGFP and EGFP alone as negative controls and of Vx3-EGFP and Vx3K0-EGFP as inhibitors (Supplementary Fig. 5 ). At most transfection levels, the negative control Vx3NB-mEGFP had little effect on the NF-κB-activation status of unstimulated cells; however, we note that some constitutive NF-κB activation was apparent at very high transfection levels of all plasmids. This constitutive activation seemed worse for transient transfection than for retroviral transduction, and worse in U2OS cells than in HeLa cells and MEFs, but the effect was somewhat variable from experiment to experiment depending on transfection conditions, the precise time between transfection and fixation, and the inhibitor expression level.
